Cargando…
Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction
BACKGROUND: This study was designed to prospectively evaluate the efficacy of extracorporeal photopheresis (ECP) to attenuate the rate of decline of FEV(1) in lung transplant recipients with refractory bronchiolitis obliterans. Due to an observed higher than expected early mortality, a preliminary a...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453798/ https://www.ncbi.nlm.nih.gov/pubmed/33955079 http://dx.doi.org/10.1111/tme.12779 |
_version_ | 1784570348891537408 |
---|---|
author | Hage, Chadi A. Klesney‐Tait, Julia Wille, Keith Arcasoy, Selim Yung, Gordon Hertz, Marshall Chan, Kevin M. Morrell, Matt Goldberg, Hilary Vedantham, Suresh Derfler, Mary Clare Commean, Paul Berman, Keith Spitznagel, Ed Atkinson, Jeff Despotis, George |
author_facet | Hage, Chadi A. Klesney‐Tait, Julia Wille, Keith Arcasoy, Selim Yung, Gordon Hertz, Marshall Chan, Kevin M. Morrell, Matt Goldberg, Hilary Vedantham, Suresh Derfler, Mary Clare Commean, Paul Berman, Keith Spitznagel, Ed Atkinson, Jeff Despotis, George |
collection | PubMed |
description | BACKGROUND: This study was designed to prospectively evaluate the efficacy of extracorporeal photopheresis (ECP) to attenuate the rate of decline of FEV(1) in lung transplant recipients with refractory bronchiolitis obliterans. Due to an observed higher than expected early mortality, a preliminary analysis was performed. STUDY DESIGN AND METHODS: Subjects from 10 lung transplant centres were assigned to ECP treatment or to observation based on spirometric criteria, with potential crossover for those under observation. The primary endpoint of this study was to assess response to ECP (i.e., greater than a 50% decrease in the rate of FEV(1) decline) before and 6 months after initiation of ECP. Mortality was also evaluated 6 and 12 months after enrolment as a secondary endpoint. RESULTS: Of 44 enrolled subjects, 31 were assigned to ECP treatment while 13 were initially assigned to observation on a non‐random basis using specific spirometric inclusion criteria (seven of the observation patients subsequently crossed over to receive ECP). Of evaluable patients, 95% of patients initially assigned to treatment responded to ECP with rates of FEV(1) decline that were reduced by 93% in evaluable ECP‐treated patients. Mortality rates (percentages) at 6 and 12 months after enrolment was 32% and 41%, respectively. The most common (92%) primary cause of death was respiratory or graft failure. Significantly (p = 0.002) higher rates of FEV(1) decline were observed in the non‐survivors (−212 ± 177 ml/month) when compared to the survivors (−95 ± 117 ml/month) 12 months after enrolment. In addition, 18 patients with bronchiolitis obliterans syndrome (BOS) diagnosis within 6 months of enrolment had lost 38% of their baseline lung function at BOS diagnosis and 50% of their lung function at enrolment. CONCLUSIONS: These analyses suggest that earlier detection and treatment of BOS should be considered to appreciate improved outcomes with ECP. |
format | Online Article Text |
id | pubmed-8453798 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-84537982021-09-27 Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction Hage, Chadi A. Klesney‐Tait, Julia Wille, Keith Arcasoy, Selim Yung, Gordon Hertz, Marshall Chan, Kevin M. Morrell, Matt Goldberg, Hilary Vedantham, Suresh Derfler, Mary Clare Commean, Paul Berman, Keith Spitznagel, Ed Atkinson, Jeff Despotis, George Transfus Med Original Articles BACKGROUND: This study was designed to prospectively evaluate the efficacy of extracorporeal photopheresis (ECP) to attenuate the rate of decline of FEV(1) in lung transplant recipients with refractory bronchiolitis obliterans. Due to an observed higher than expected early mortality, a preliminary analysis was performed. STUDY DESIGN AND METHODS: Subjects from 10 lung transplant centres were assigned to ECP treatment or to observation based on spirometric criteria, with potential crossover for those under observation. The primary endpoint of this study was to assess response to ECP (i.e., greater than a 50% decrease in the rate of FEV(1) decline) before and 6 months after initiation of ECP. Mortality was also evaluated 6 and 12 months after enrolment as a secondary endpoint. RESULTS: Of 44 enrolled subjects, 31 were assigned to ECP treatment while 13 were initially assigned to observation on a non‐random basis using specific spirometric inclusion criteria (seven of the observation patients subsequently crossed over to receive ECP). Of evaluable patients, 95% of patients initially assigned to treatment responded to ECP with rates of FEV(1) decline that were reduced by 93% in evaluable ECP‐treated patients. Mortality rates (percentages) at 6 and 12 months after enrolment was 32% and 41%, respectively. The most common (92%) primary cause of death was respiratory or graft failure. Significantly (p = 0.002) higher rates of FEV(1) decline were observed in the non‐survivors (−212 ± 177 ml/month) when compared to the survivors (−95 ± 117 ml/month) 12 months after enrolment. In addition, 18 patients with bronchiolitis obliterans syndrome (BOS) diagnosis within 6 months of enrolment had lost 38% of their baseline lung function at BOS diagnosis and 50% of their lung function at enrolment. CONCLUSIONS: These analyses suggest that earlier detection and treatment of BOS should be considered to appreciate improved outcomes with ECP. Blackwell Publishing Ltd 2021-05-05 2021-08 /pmc/articles/PMC8453798/ /pubmed/33955079 http://dx.doi.org/10.1111/tme.12779 Text en © 2021 The Authors. Transfusion Medicine published by John Wiley & Sons Ltd on behalf of British Blood Transfusion Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Hage, Chadi A. Klesney‐Tait, Julia Wille, Keith Arcasoy, Selim Yung, Gordon Hertz, Marshall Chan, Kevin M. Morrell, Matt Goldberg, Hilary Vedantham, Suresh Derfler, Mary Clare Commean, Paul Berman, Keith Spitznagel, Ed Atkinson, Jeff Despotis, George Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction |
title | Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction |
title_full | Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction |
title_fullStr | Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction |
title_full_unstemmed | Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction |
title_short | Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction |
title_sort | extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453798/ https://www.ncbi.nlm.nih.gov/pubmed/33955079 http://dx.doi.org/10.1111/tme.12779 |
work_keys_str_mv | AT extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction AT hagechadia extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction AT klesneytaitjulia extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction AT willekeith extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction AT arcasoyselim extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction AT yunggordon extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction AT hertzmarshall extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction AT chankevinm extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction AT morrellmatt extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction AT goldberghilary extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction AT vedanthamsuresh extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction AT derflermaryclare extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction AT commeanpaul extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction AT bermankeith extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction AT spitznageled extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction AT atkinsonjeff extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction AT despotisgeorge extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction |